Close Menu

Regulus

People in the News: Jan 6, 2011

Premium

Dale Pfost, Garry Menzel

Despite the mounting data linking a variety of miRNAs to different diseases, in most cases the data are early-stage, and thus far only a handful of miRNAs have made it into the pipelines of companies in the field.

Included in Alnylam's pipeline is a preclinical program in hypercholesterolemia, which remains on track to yield an investigational new drug application filing next year and will incorporate a new lipid-nanoparticle delivery technology developed in collaboration with Tekmira Pharmaceuticals.

In June, Regulus announced that it had inked a deal giving Sanofi-Aventis the worldwide, exclusive rights to use its technology and know-how to discover, develop, and commercialize miRNA drugs, including a fibrosis treatment targeting miR-21.

Adding to the difficulty in raising funds, there has also been an increase in the number of companies operating in the miRNA space in recent years, many of which are on the lookout for their share of available investment dollars.

While the company remains optimistic about the drug's potential, questions remain as to whether Santaris has the intellectual property necessary to bring it to market.

The financial reporting manager being sought will help create "procedures to ensure that Regulus is fully compliant and ready to become a publicly traded organization," according to Regulus.

The microRNA is a potential target for immuno-inflammatory disorders and part of a lead program in the company's collaboration with GlaxoSmithKline, Regulus said.

Rosetta Genomics top executive said this week that the firm expects to forge at least one strategic partnership by year end, although he did not specify whether it would be around its diagnostics, drug research biomarker, or therapeutics efforts.

The deal gives Sanofi worldwide, exclusive rights to use Regulus' technology and know-how to discover, develop, and sell four miRNA drugs.

Pages

A South African university has told the Wellcome Sanger Institute to return DNA samples it has from indigenous African communities, The Times reports.

The University of California, Berkeley's Rasmus Nielsen and Xinzhu Wei have retracted their CCR5 gene paper due to a technical artifact.

 

University of Virginia researchers are exploring a genetic risk test to gauge type 1 diabetes risk, NPR reports.

In PNAS this week: researchers compare two high-grade neuroendocrine lung cancers, height among ancient Europeans, and more.